Brian Abrahams
Stock Analyst at RBC Capital
(2.28)
# 2,690
Out of 5,142 analysts
445
Total ratings
44.54%
Success rate
-3.85%
Average return
Main Sectors:
Stocks Rated by Brian Abrahams
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PRTA Prothena Corporation | Maintains: Sector Perform | $11 → $12 | $9.07 | +32.30% | 13 | Feb 20, 2026 | |
| PTCT PTC Therapeutics | Maintains: Sector Perform | $87 → $82 | $70.50 | +16.31% | 24 | Feb 20, 2026 | |
| MLTX MoonLake Immunotherapeutics | Maintains: Sector Perform | $10 → $12 | $18.68 | -35.76% | 4 | Feb 20, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintains: Outperform | $546 → $541 | $481.01 | +12.47% | 58 | Feb 13, 2026 | |
| NBIX Neurocrine Biosciences | Maintains: Outperform | $180 → $177 | $128.38 | +37.87% | 25 | Feb 12, 2026 | |
| INCY Incyte | Maintains: Sector Perform | $95 → $92 | $100.85 | -8.77% | 25 | Feb 11, 2026 | |
| GILD Gilead Sciences | Maintains: Sector Perform | $103 → $118 | $149.83 | -21.24% | 35 | Feb 11, 2026 | |
| BIIB Biogen | Maintains: Outperform | $217 → $233 | $196.34 | +18.67% | 42 | Feb 9, 2026 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Outperform | $35 → $31 | $24.73 | +25.35% | 4 | Feb 3, 2026 | |
| BCRX BioCryst Pharmaceuticals | Maintains: Outperform | $14 → $13 | $7.58 | +71.50% | 20 | Jan 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $28 → $30 | $15.38 | +95.06% | 1 | Jan 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $40 | $15.42 | +159.40% | 2 | Jan 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $36 | $16.95 | +112.39% | 1 | Jan 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $70 → $83 | $69.91 | +18.72% | 3 | Jan 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $103 | $88.43 | +16.48% | 2 | Dec 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $24 | $36.10 | -33.52% | 2 | Dec 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $4 → $7 | $3.45 | +102.90% | 7 | Dec 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $22 | $15.64 | +40.66% | 6 | Nov 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $19 → $18 | $12.58 | +43.08% | 5 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $55 → $53 | $7.42 | +614.29% | 9 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $1.5 → $1 | $1.01 | -0.99% | 2 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $3 → $2 | $1.23 | +62.60% | 14 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $28 → $32 | $33.87 | -5.52% | 13 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $55 → $58 | $42.72 | +35.77% | 20 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $19 | $10.03 | +89.43% | 13 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $704 → $708 | $787.04 | -10.04% | 35 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $25 → $23 | $18.12 | +26.93% | 35 | Jul 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $84 | $19.75 | +325.32% | 1 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $139 → $143 | $174.76 | -18.17% | 2 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $40 | $36.17 | +10.59% | 1 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $25 → $15 | $13.49 | +11.19% | 14 | Oct 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $12 → $9 | $3.97 | +126.70% | 3 | Mar 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $22.51 | - | 4 | Dec 4, 2017 |
Prothena Corporation
Feb 20, 2026
Maintains: Sector Perform
Price Target: $11 → $12
Current: $9.07
Upside: +32.30%
PTC Therapeutics
Feb 20, 2026
Maintains: Sector Perform
Price Target: $87 → $82
Current: $70.50
Upside: +16.31%
MoonLake Immunotherapeutics
Feb 20, 2026
Maintains: Sector Perform
Price Target: $10 → $12
Current: $18.68
Upside: -35.76%
Vertex Pharmaceuticals
Feb 13, 2026
Maintains: Outperform
Price Target: $546 → $541
Current: $481.01
Upside: +12.47%
Neurocrine Biosciences
Feb 12, 2026
Maintains: Outperform
Price Target: $180 → $177
Current: $128.38
Upside: +37.87%
Incyte
Feb 11, 2026
Maintains: Sector Perform
Price Target: $95 → $92
Current: $100.85
Upside: -8.77%
Gilead Sciences
Feb 11, 2026
Maintains: Sector Perform
Price Target: $103 → $118
Current: $149.83
Upside: -21.24%
Biogen
Feb 9, 2026
Maintains: Outperform
Price Target: $217 → $233
Current: $196.34
Upside: +18.67%
ACADIA Pharmaceuticals
Feb 3, 2026
Maintains: Outperform
Price Target: $35 → $31
Current: $24.73
Upside: +25.35%
BioCryst Pharmaceuticals
Jan 30, 2026
Maintains: Outperform
Price Target: $14 → $13
Current: $7.58
Upside: +71.50%
Jan 29, 2026
Maintains: Outperform
Price Target: $28 → $30
Current: $15.38
Upside: +95.06%
Jan 23, 2026
Maintains: Outperform
Price Target: $33 → $40
Current: $15.42
Upside: +159.40%
Jan 23, 2026
Maintains: Outperform
Price Target: $20 → $36
Current: $16.95
Upside: +112.39%
Jan 22, 2026
Downgrades: Sector Perform
Price Target: $70 → $83
Current: $69.91
Upside: +18.72%
Dec 16, 2025
Maintains: Outperform
Price Target: $70 → $103
Current: $88.43
Upside: +16.48%
Dec 1, 2025
Downgrades: Underperform
Price Target: $24
Current: $36.10
Upside: -33.52%
Dec 1, 2025
Upgrades: Outperform
Price Target: $4 → $7
Current: $3.45
Upside: +102.90%
Nov 21, 2025
Maintains: Outperform
Price Target: $25 → $22
Current: $15.64
Upside: +40.66%
Nov 14, 2025
Maintains: Outperform
Price Target: $19 → $18
Current: $12.58
Upside: +43.08%
Nov 13, 2025
Maintains: Outperform
Price Target: $55 → $53
Current: $7.42
Upside: +614.29%
Nov 7, 2025
Maintains: Sector Perform
Price Target: $1.5 → $1
Current: $1.01
Upside: -0.99%
Nov 7, 2025
Maintains: Sector Perform
Price Target: $3 → $2
Current: $1.23
Upside: +62.60%
Nov 7, 2025
Maintains: Sector Perform
Price Target: $28 → $32
Current: $33.87
Upside: -5.52%
Nov 4, 2025
Maintains: Outperform
Price Target: $55 → $58
Current: $42.72
Upside: +35.77%
Nov 4, 2025
Maintains: Outperform
Price Target: $30 → $19
Current: $10.03
Upside: +89.43%
Oct 29, 2025
Maintains: Sector Perform
Price Target: $704 → $708
Current: $787.04
Upside: -10.04%
Jul 17, 2025
Maintains: Sector Perform
Price Target: $25 → $23
Current: $18.12
Upside: +26.93%
Apr 22, 2025
Reiterates: Outperform
Price Target: $84
Current: $19.75
Upside: +325.32%
Feb 3, 2025
Maintains: Outperform
Price Target: $139 → $143
Current: $174.76
Upside: -18.17%
Jan 28, 2025
Reiterates: Outperform
Price Target: $40
Current: $36.17
Upside: +10.59%
Oct 2, 2023
Maintains: Sector Perform
Price Target: $25 → $15
Current: $13.49
Upside: +11.19%
Mar 31, 2022
Maintains: Sector Perform
Price Target: $12 → $9
Current: $3.97
Upside: +126.70%
Dec 4, 2017
Upgrades: Buy
Price Target: n/a
Current: $22.51
Upside: -